Purpose: Belotecan (Camtobell Ⓡ ; Chong Keun Dang Co., Seoul, Korea) is a new camptothecin analog that inhibits topoisomerase I. We evaluated the efficacy and toxicity of belotecan combined with cisplatin in patients with previously untreated extensive-disease small cell lung cancer (ED-SCLC) and who were without evidence of brain metastases. 
INTRODUCTION
Camptothecin (CPT) is a potent antineoplastic molecule obtained from extracts of the Chinese tree Camptotheca acuminanata. The cytotoxic activity of CPT is attributed to a novel mechanism of action involving the nuclear enzyme type I DNA topoisomerase (1) , and two derivatives, topotecan and irinotecan, have successfully entered the market and are used as topoisomerase I inhibitors in clinical practice.
Belotecan (Camtobell Ⓡ ; Chong Keun Dang Co., Seoul, Korea), a water-soluble CPT analog also known as CKD-602, was introduced to treat small cell lung cancer (SCLC). In preclinical studies, belotecan was more potent as a topoisomerase I inhibitor and had more antitumor activity than camptothecin or topotecan (Hycamtin Ⓡ ; GlaxoSmithKline, Brentford, UK) in six human tumor xenografts (2, 3) . Recently, a phase II study using the single agent belotecan in chemotherapy naïve patients with extensive disease (ED)-SCLC showed a promising response rate of 53.2%. The median overall survival was 10.4 months, the median time to progression was 4.6 months, and the 1-year survival rate was 49.9% (4) . The most common toxicity was hematologic (grade 3/4 neutropenia, 71.0% of patients; grade 3/4 thrombocytopenia, 12.9%) (4).
Potent antitumor activity against SCLC was noted in a phase I study of belotecan plus cisplatin, with a response rate of 76.5%, a median survival of 15.9 months, and reasonable non-hematologic toxicities (5) . Based on these findings, we investigated the efficacy and toxicity profile of this regimen in previously untreated patients with ED-SCLC.
MATERIALS AND METHODS

1) Eligibility criteria
Patients from two centers, Chungnam National University
Hospital and Konkuk University Hospital, were enrolled in the study. All patients had histologically or cytologically confirmed SCLC with evidence of ED, excluding brain metastases.
Patients had to meet the following criteria: at least one unidimensionally measurable or assessable lesion; age ≥18
years, Eastern Cooperative Oncology Group performance status (PS) ≤3, absolute neutrophil count ≥1,500/mm 3 , hemoglobin ＞10.0 g/dL, platelet count ≥100,000/μL, aspartate and alanine aminotransferase levels ≤2-fold the upper limit of normal, bilirubin ≤1.5 mg/dL, creatinine ≤1.5 mg/dL, or a calculated creatinine clearance ＞60 mL/min. Patients were not eligible for the study if they had any of the following: active infection, history of myocardial infarction within the last 6 months, congestive heart failure or significant arrhythmia, uncontrolled pleural or pericardial effusion or ascites, or a second primary cancer. The pretreatment assessment included chest radiography, computed tomography of the thorax and brain, a radionuclide bone scan, positron-emission tomography/ computed tomography, and fiberoptic bronchoscopy. Pulmonary function studies and arterial blood gas measurements were also conducted when signs or symptoms of respiratory insufficiency were present. This study was approved by the ethics committees of the two participating centers. Written informed consent was obtained from all patients before the study.
2) Treatment
Chemotherapy consisted of cisplatin (60 mg/m 2 ) on day 1 and belotecan (0.5 mg/m 2 /day) on days 1 to 4 for 3 weeks. The dose and schedule were based on a study conducted previously (5) . Cisplatin was diluted to 150 mL in normal saline and administered as a 60-min intravenous infusion on day 1.
Patients received standard intravenous hydration with 1,000 mL of 5% dextrose or normal saline for 2 hours before and after cisplatin administration. A standard antiemetic combination of 10 mg dexamethasone and 8 mg dolasetron was administered by intravenous infusion before the cisplatin administration.
Belotecan was diluted in 100 mL of 5% dextrose in water for injection and was immediately administered in a 30-min intravenous infusion once per day on days 1 to 4.
During the treatment cycle, belotecan combined with cisplatin treatment was delayed for 1 week if any of the following conditions were present on day 1 of the planned treatment: absolute neutrophil count (ANC) ＜1,500/mm 3 , platelet count ＜100,000/mm 3 , or non-hematologic toxicity ＞ grade 2. If any of the following conditions were present, the chemotherapy dose was reduced to 80% of the planned dosage:
ANC nadir of ＜500/mm 3 for 4 or more days, febrile neutropenia, platelet nadir count of ＜50,000/mm 3 for 4 or more days, thrombocytopenia associated with a bleeding episode, or non-hematologic toxicity ≥grade 4. Treatment interruptions or delays due to unacceptable toxicity were not allowed for ≥2
weeks. Prophylactic use of granulocyte-colony-stimulating factor was not allowed, but it could be used therapeutically.
The treatments were given for ≥6 cycles, unless disease progression or unacceptable toxicity occurred.
3) Response and toxicity criteria
Tumor responses were assessed every two cycles according to the Response Evaluation Criteria in Solid Tumors. A complete response (CR) was defined as the disappearance of all target lesions, while a partial response (PR) was defined as a decrease of ≥30% in the sum of the greatest dimensions of the target lesions taken as a reference of the baseline sum for the greatest dimensions and/or the persistence of one or more nontarget lesion(s). Progressive disease (PD) was defined as an increase of ≥20% in the sum of the greatest dimensions using the smallest sum of the greatest dimensions recorded since starting treatment as a reference, or the appearance of one or more new lesions, and/or unequivocal progression of existing nontarget lesions. Stable disease (SD) was defined as neither sufficient shrinkage to qualify as PR nor a sufficient increase to qualify as PD using the smallest sum of the greatest dimensions observed since starting treatment as the reference.
Descriptive statistics are reported as proportions and medians. Overall survival (OS) was defined as the time from treatment initiation to death or to the last known follow-up.
Progression-free survival (PFS) was defined as the time between treatment initiation and disease progression, death, or Ten patients received retreatment with etoposide plus cisplatin (EP) after recurrence. Five patients achieved PR, three patients had SD, and two patients had PD.
Toxicity was evaluated in all 20 patients, who received 106 treatment cycles (median cycles/patient, 5.5; range, 1∼9). The major toxicities observed were hematologic (Table 3) . Grade 3 
DISCUSSION AND CONCLUSION
The present study showed a high response rate (84.2%) and acceptable toxicities for treatment with belotecan plus cisplatin.
The results were similar to those of a phase I study with a response rate of 76.5% (5). However, accepting the median OS and PFS was difficult because of the small sample size. Recently, a phase II belotecan and cisplatin study in chemotherapy naïve patients (n=30) with ED-SCLC showed promising response rates (70%), PFS (6.9 months), and OS (19.2 months). Grade 3/4 neutropenia was 76%, and no diarrhea occurred. The response rate and the disease control rate with subsequent second-line therapy (mainly etoposide and platinum)
were 23.5% and 52.9%, respectively, which may have led to a better survival outcome (12) .
This study showed a high response rate and acceptable toxicities for belotecan plus cisplatin treatment. The results should be reinforced by studies with an increased sample size and longer follow-up time.
Combination chemotherapy with belotecan plus cisplatin was active as a first-line therapy for patients with ED-SCLC, with acceptable hematologic and non-hematologic toxicities.
